Molecular radionuclide therapy-induced salivary gland toxicity: an unappreciated threat to patients' quality of life?
- PMID: 38586985
- DOI: 10.1097/MNM.0000000000001839
Molecular radionuclide therapy-induced salivary gland toxicity: an unappreciated threat to patients' quality of life?
References
-
- Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov 2020; 19:589–608.
-
- Jarzab B, Handkiewicz-Junak D, Wloch J. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocr Relat Cancer 2005; 12:773–803.
-
- Jellema AP, Slotman BJ, Doornaert P, Leemans CR, Langendijk JA. Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 69:751–760.
-
- Dawes C. How much saliva is enough for avoidance of xerostomia? Caries Res 2004; 38:236–240.
-
- An YS, Yoon J-K, Lee SJ, Song H-S, Yoon S-H, Jo K-S. Symptomatic late-onset sialadenitis after radioiodine therapy in thyroid cancer. Ann Nucl Med 2013; 27:386–391.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources